nach oben

Erschienen in:

01.05.2015 | Case Report

A case of clonally distinct relapse of Burkitt lymphoma 9 years after complete remission

verfasst von: Minoru Kojima, Naoya Nakamura, Miharu Yabe, Mami Tokunaka, Yara Yukie Kikuti, Tomoki Kikuchi, Hiromichi Murayama, Makiko Moriuchi, Kosuke Tsuboi, Yoshiaki Ogawa, Kiyoshi Ando

Erschienen in: International Journal of Hematology | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

We report a case of HIV-negative Burkitt lymphoma (BL) that relapsed 9 years after complete remission. We performed a polymerase chain reaction analysis of three regions of the VDJ junction of the immunoglobulin heavy chain (IGH) gene and compared the clonality of the first and second BL lesions, which were found to be clonally distinct. The patient received the R-Hyper CVAD/R-MA regimen; however, leukoencephalopathy subsequently developed due to the effect of cytarabine, and the regimen was changed to R-IVAM. The patient achieved complete remission and received high-dose chemotherapy following autologous stem cell transplantation. He maintained the complete remission for 72 months after transplantation. Given this outcome, we suggest that clonally distinct relapse of HIV-negative BL may exhibit a good prognosis.

Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117:5019–32.CrossRefPubMedCentralPubMed

Burkitt DP. Etiology of Burkitt’s lymphoma—an alternative hypothesis to a vectored virus. J Natl Cancer Inst. 1969;42(1):19–28.PubMed

Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, Cairo MS, FAB/LMB96 International Study Committee. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109(7):2773–80.PubMedCentralPubMed

Magrath IT, Janus C, Edwards BK, Spiegel R, Jaffe ES, Berard CW, Miliauskas J, Morris K, Barnwell R. An effective therapy for both undifferentiated (including Burkitt’s) lymphomas and lymphoblastic lymphomas in children and young adults. Blood. 1984;63(5):1102–11.PubMed

Soussain C, Patte C, Ostronoff M, Delmer A, Rigal-Huguet F, Cambier N, Leprisé PY, François S, Cony-Makhoul P, Harousseau JL, et al. Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood. 1995;85(3):664–74.PubMed

Wästerlid T, Brown PN, Hagberg O, Hagberg H, Pedersen LM, D’Amore F, Jerkeman M. Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. Ann Oncol. 2013;24(7):1879–86.CrossRefPubMed

Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, Widemann B, Staudt LM, Jaffe ES, Little RF, Wilson WH. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369(20):1915–25.CrossRefPubMedCentralPubMed

Kikuchi A, Mori T, Fujimoto J, Kumagai M, Sunami S, Okimoto Y, Tsuchida M. Outcome of childhood B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia treated with the Tokyo Children’s Cancer Study Group NHL B9604 protocol. Leuk Lymphoma. 2008;49(4):757–62.CrossRefPubMed

Nakamura N, Kuze T, Hashimoto Y, Hara Y, Hoshi S, Sasaki Y, Shirakawa A, Sato M, Abe M. Analysis of the immunoglobulin heavy chain gene variable region of CD5-positive and -negative diffuse large B cell lymphoma. Leukemia. 2001;15(3):452–7.CrossRefPubMed

10.

Nishiuchi R, Yoshino T, Teramoto N, Sakuma I, Hayashi K, Nakamura S, Seino Y, Akagi T. Clonal analysis by polymerase chain reaction of B-cell lymphoma with late relapse: a report of five cases. Cancer. 1996;77(4):757–62.CrossRefPubMed

11.

Libra M, De Re V, Gloghini A, Navolanic PM, Carbone A, Boiocchi M. Second primary lymphoma or recurrence: a dilemma solved by VDJ rearrangement analysis. Leuk Lymphoma. 2004;45(8):1539–43.CrossRefPubMed

12.

Sweetenham JW, Pearce R, Taghipour G, Blaise D, Gisselbrecht C, Goldstone AH. Adult Burkitt’s and Burkitt-like non-Hodgkin’s lymphoma—outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. J Clin Oncol. 1996;14(9):2465–72.PubMed

13.

Ziegler JL, Bluming AZ, Fass L, Morrow RH Jr. Relapse patterns in Burkitt’s lymphoma. Cancer Res. 1972;32(6):1267–72.PubMed

14.

Lister J, Miklos JA, Swerdlow SH, Bahler DW. A clonally distinct recurrence of Burkitt’s lymphoma at 15 years. Blood. 1996;88(4):1407–10.PubMed

15.

Nguyen JT, Kini AR, Li Y, Sarvida ME, Manera R. Analysis of immunoglobulin heavy chain rearrangement in a child with recurrent Burkitt lymphoma to determine clonality. J Pediatr Hematol Oncol. 2014;36(2):e125–7.CrossRefPubMed

Titel: A case of clonally distinct relapse of Burkitt lymphoma 9 years after complete remission
verfasst von: Minoru Kojima
Naoya Nakamura
Miharu Yabe
Mami Tokunaka
Yara Yukie Kikuti
Tomoki Kikuchi
Hiromichi Murayama
Makiko Moriuchi
Kosuke Tsuboi
Yoshiaki Ogawa
Kiyoshi Ando
Publikationsdatum: 01.05.2015
Verlag: Springer Japan
Erschienen in: International Journal of Hematology / Ausgabe 5/2015
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-014-1729-1

Springer Medizin

A case of clonally distinct relapse of Burkitt lymphoma 9 years after complete remission

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2015

Clinical significance of nontuberculous mycobacteria from respiratory specimens in stem cell transplantation recipients

Therapeutic benefits targeting B-cells in chronic graft-versus-host disease

Intestinal microbiota-related effects on graft-versus-host disease

Study of correlation between state and composition of lipid phase and change in erythrocytes structure under induction of oxidative processes

State-of-the-art acute and chronic GVHD treatment

Recent topics in graft-versus-host disease: from the perspectives of pathogenesis and treatment

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie